Damora Therapeutics (DMRA) Share-based Compensation (2020 - 2026)
Damora Therapeutics (DMRA) reported Share-based Compensation of $8.1 million for Q1 2026, up 4435.2% on a YoY basis from $179000.0 in Q1 2025, and up 1580.75% quarter-over-quarter from $483000.0 in Q4 2025.
Damora Therapeutics (DMRA) Share-based Compensation (2020 - 2026) Analysis & Trends
Damora Therapeutics has reported Share-based Compensation for 7 years, with the latest figure at $8.1 million in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation rose 4435.2% year-over-year to $8.1 million; the trailing twelve-month figure through Mar 2026 stood at $8.9 million (up 334.05% YoY), and the FY2025 full-year result was $998000.0, down 69.19% from the prior year.
- Share-based Compensation for Q1 2026 stood at $8.1 million, up from $483000.0 in the prior quarter.
- The five-year high for Share-based Compensation was $8.1 million in Q1 2026, with the low at $164000.0 in Q3 2025.
- Historically, Share-based Compensation has averaged $1.4 million across 5 years, with a median of $1.3 million in 2022.
- Annual changes were most pronounced in 2025 — Share-based Compensation tumbled 86.83% — and 2026, when it soared 4435.2%.
- Damora Therapeutics' Share-based Compensation stood at $1.3 million in 2022, then fell by 19.2% to $1.1 million in 2023, then slumped by 71.74% to $308000.0 in 2024, then surged by 56.82% to $483000.0 in 2025, then soared by 1580.75% to $8.1 million in 2026.
- The last three Share-based Compensation figures came in at $8.1 million (Q1 2026), $483000.0 (Q4 2025), and $164000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 26.47 Mn |
| 10 | Damora Therapeutics | 731.26 Mn | 528.86 Mn | - | 8.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.12 Mn |
| Mar 31, 2026 | 8.12 Mn |
| Dec 31, 2025 | 483,000.00 |
| Dec 31, 2025 | 483,000.00 |
| Sep 30, 2025 | 164,000.00 |
| Sep 30, 2025 | 164,000.00 |
| Jun 30, 2025 | 172,000.00 |
| Jun 30, 2025 | 172,000.00 |
| Mar 31, 2025 | 179,000.00 |
| Mar 31, 2025 | 179,000.00 |
| Dec 31, 2024 | 308,000.00 |
| Dec 31, 2024 | 308,000.00 |
| Sep 30, 2024 | 681,000.00 |
| Sep 30, 2024 | 681,000.00 |
| Jun 30, 2024 | 891,000.00 |
| Jun 30, 2024 | 891,000.00 |
| Mar 31, 2024 | 1.36 Mn |
| Mar 31, 2024 | 1.36 Mn |
| Dec 31, 2023 | 1.09 Mn |
| Dec 31, 2023 | 1.09 Mn |